Thomas W. Feeley, MD

Articles by Thomas W. Feeley, MD

How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?

ByStephen Schleicher, MD, MBA,Nancy M. Wood, MS,Seohyun Lee, MA,Thomas W. Feeley, MD

May 15th 2016

Although data are anecdotal, there is no question that the increased numbers of patients with insurance resulted in cancer patients receiving care they previously could not.

Latest Updated Articles

How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?
May 15th 2016

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?

112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial

Thomas W. Feeley, MD

Articles by Thomas W. Feeley, MD

How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?

112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial

Moving Beyond R-CHOP: The Future of Upfront Precision Oncology in Lymphoma

Overcoming Knowledge Barriers to Accessing Oncology Yoga Programs